MarketCapExport financials
Alpine Immune Sciences (ALPN)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Alpine Immune Sciences Income Statement 2023-2011 | ALPN
Brief overview of financial performance at Alpine Immune Sciences
The comparison covers a five-year financial horizon. The revenue attributed to Alpine Immune Sciences moved from $705 thousand to $58.9 million between the two endpoints. Across the full period, sales moved by +8251.2%; the average annual rate was 142.3%. Sales grew at a rate typical of a strong expansion phase.
Over the period, EBITDA shifted from −$37.4 million to −$43.7 million, a change of −16.6%. Operating performance weakened relative to revenue. The EBITDA share of revenue changed from −5310.9% to −74.2%. Higher profitability strengthens the quality of operating growth.
The net financial result changed from −36.5 million dollars to −32.2 million dollars. The direction improved, yet positive earnings are still absent.
Overall conclusion
Positive developments coexist with areas of weakness. The financial profile benefits from sales growth, positive operating leverage and net-income growth. The most visible risks are limited operating profitability. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement Alpine Immune Sciences
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
- | 269 M | 210 M | 244 M | 57.3 M | 93.7 M | 57 M | 6.17 M | 9 M | - | - | - | - |
Shares |
50 M | 33.4 M | 25.5 M | 20.8 M | 18.4 M | 13.8 M | 6.48 M | 565 K | 497 K | 723 | 155 | - | - |
Historical Prices |
- | 8.04 | 8.24 | 11.7 | 3.12 | 6.76 | 8.79 | 10.9 | 18.1 | - | - | - | - |
Net Income |
-32.2 M | -57.8 M | -50.3 M | -27.9 M | -41.9 M | -36.5 M | -7.78 M | -1.23 M | -369 K | -14.7 M | -16.2 M | -9.57 M | - |
Revenue |
58.9 M | 30.1 M | 23.4 M | 9.34 M | 1.74 M | 705 K | 1.73 M | 2.95 M | - | - | - | - | - |
Operating Income |
-44.2 M | -58.1 M | -49.9 M | -28.7 M | -43.6 M | -37.8 M | -15 M | -1.19 M | -371 K | -14.5 M | -15.3 M | - | - |
Interest Expense |
98 K | 476 K | 816 K | 775 K | 338 K | 319 K | 152 K | - | - | 845 K | 931 K | - | - |
EBITDA |
-43.7 M | -57.6 M | -49.2 M | -28.2 M | -43.1 M | -37.4 M | -14.7 M | -1.12 M | -370 K | -14.4 M | -15.1 M | -8.67 M | - |
Operating Expenses |
103 M | 88.2 M | 73.3 M | 38.1 M | 45.3 M | 38.5 M | 16.7 M | 4.14 M | 863 K | 14.5 M | - | - | - |
General and Administrative Expenses |
22.2 M | 18 M | 14.6 M | 10.9 M | 9.47 M | 8.36 M | 6.08 M | 1.15 M | 441 K | 2.29 M | 2.14 M | 1.93 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Alpine Immune Sciences
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
64 M | 60.3 M | 49.2 M | 48 M | 47.6 M | 46 M | 31.6 M | 30.3 M | 30.3 M | 30.2 M | 24.7 M | 23.9 M | 23.9 M | 23.8 M | 22.3 M | 18.6 M | 18.6 M | 18.6 M | 18.6 M | 18.6 M | 17.7 M | 13.9 M | 13.9 M | 13.8 M | 13.8 M | 13.8 M | 10.6 M | 15.7 M | 15.6 M | 15.5 K | 15.5 M | 15.5 M | 15.5 M | 15.5 K | 15.5 M | 4.16 M | 2.21 M | 2.21 K | 343 K | 163 K | 161 | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-17.9 M | - | -11.7 M | -13.2 M | -13.3 M | - | -13.3 M | -18.1 M | -7.53 M | - | -13.5 M | -11 M | -10.6 M | - | -6.14 M | -9.93 M | -5.53 M | - | -11.5 M | -11.9 M | -12.4 M | - | -12.1 M | -7.91 M | -5.31 M | - | 2.12 M | -3.71 M | -8.92 M | -7.71 M | -7.43 M | -8.48 M | -7.84 M | -6.56 M | -6.09 M | -10.2 M | -4.31 M | -3.49 M | -2.63 M | -4.19 M | -4.35 M | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
7.03 M | - | 10 M | 8.59 M | 9.39 M | - | 8.37 M | 5.29 M | 13.6 M | - | 8.52 M | 7.19 M | 3.2 M | - | 1.91 M | 688 K | 1.09 M | - | 289 K | 567 K | - | - | - | 390 K | 315 K | - | 128 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-22.7 M | - | -14.6 M | -15.7 M | -15.6 M | - | -13.8 M | -16.5 M | -7.46 M | - | -13.3 M | -10.7 M | -10.5 M | - | -6.97 M | -9.75 M | -5.56 M | - | -11.7 M | -12.2 M | -12.7 M | - | -12.4 M | -8.41 M | -5.58 M | - | -4.55 M | -3.82 M | -9.02 M | -7.82 M | -7.55 M | -8.6 M | -7.93 M | -6.63 M | -6.1 M | -5.85 M | -4.32 M | -3.49 M | -2.65 M | -3.96 M | -4.39 M | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
- | - | - | 28 K | 70 K | - | 105 K | 130 K | 154 K | - | 203 K | 218 K | 217 K | - | 214 K | 226 K | 120 K | - | 66 K | 61 K | 70 K | - | 82 K | 83 K | 78 K | - | 75 K | 1 K | - | - | - | - | - | - | 392 K | 241 K | - | - | 392 K | 241 K | 212 K | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-22.5 M | - | -14.1 M | -15.4 M | -15.5 M | - | -13.4 M | -16.2 M | -7.31 M | - | -12.8 M | -10.4 M | -10.3 M | - | -6.55 M | -9.47 M | -5.43 M | - | -11.4 M | -11.9 M | -12.4 M | - | -12.1 M | -8.24 M | -5.5 M | - | -4.39 M | -3.71 M | -8.97 M | -7.82 M | -7.44 M | -8.53 M | -7.9 M | -6.63 M | -6.05 M | -5.82 M | -4.3 M | -3.49 M | -2.58 M | -3.9 M | -4.39 M | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
29.7 M | - | 24.6 M | 24.2 M | 25 M | - | 22.2 M | 21.8 M | 21.1 M | - | 21.8 M | 17.9 M | 13.7 M | - | 8.88 M | 10.4 M | 6.66 M | - | 12 M | 12.7 M | 12.7 M | - | 12.4 M | 8.8 M | 5.9 M | - | 4.68 M | 4.38 M | 2.73 M | - | 1.12 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
7.27 M | - | 5.44 M | 5.01 M | 5.4 M | - | 4.61 M | 4.19 M | 4.78 M | - | 3.47 M | 3.29 M | 3.26 M | - | 2.73 M | 3.34 M | 1.78 M | - | 2.47 M | 2.55 M | 2.34 M | - | 1.86 M | 1.88 M | 2.11 M | - | 1.93 M | 2.59 M | 2.78 M | 2.17 M | 1.88 M | 2.17 M | 2.37 M | 2.34 M | 1.82 M | 1.39 M | 1.3 M | 664 K | 490 K | 594 K | 539 K | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Alpine Immune Sciences (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Russia
USA
Canada
Niderland
Israel
Spain
Germany
Australia
Britain
